These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32999503)

  • 21. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Jul; 51(14):1792-9. PubMed ID: 7942908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.
    Housman ST; Tessier PR; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2011 Dec; 68(23):2265-70. PubMed ID: 22095816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
    Katip W
    Am J Health Syst Pharm; 2017 Jul; 74(14):1099-1102. PubMed ID: 28687555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical and chemical compatibility of injectable acetaminophen during simulated y-site administration.
    Anderson C; Boehme S; Ouellette J; Stidham C; Mackay M
    Hosp Pharm; 2014 Jan; 49(1):42-7. PubMed ID: 24421562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ; Demmon SL; Boelk DA; Payne CA; Effron MB; Rajagopalan N; Williams MD; Beck GM; Gopalrathnam G
    Am J Health Syst Pharm; 2004 Dec; 61(24):2664-71. PubMed ID: 15646701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compatibility of amifostine with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 Oct; 52(20):2208-12. PubMed ID: 8564592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
    Lu J; Liu Q; Kupiec TC; Vail H; Lynch LR; Fam DS; Vu NT
    Int J Pharm Compd; 2021; 25(1):52-61. PubMed ID: 33503010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.
    Kidd JM; Avery LM; Asempa TE; Nicolau DP; Kuti JL
    Clin Ther; 2018 Feb; 40(2):261-269. PubMed ID: 29290374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compatibility of aztreonam with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 May; 52(10):1086-90. PubMed ID: 7656099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.
    So W; Kim L; Thabit AK; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2017 Jan; 74(1):e55-e63. PubMed ID: 28007722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
    Trissel LA; Bready BB
    Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
    Holyk AA; Lindner AH; Lindner SE; Shippert BW
    Am J Health Syst Pharm; 2022 Jan; 79(1):e27-e33. PubMed ID: 34390244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compatibility of filgrastim with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Aug; 51(15):1907-13. PubMed ID: 7524319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
    Avery LM; Chen IH; Reyes S; Nicolau DP; Kuti JL
    Clin Ther; 2019 Oct; 41(10):2162-2170. PubMed ID: 31506218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Jan; 54(1):56-60. PubMed ID: 9117791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
    Trissel LA; Williams KY; Gilbert DL
    J Am Pharm Assoc (Wash); 2000; 40(4):515-9. PubMed ID: 10932461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.